News & Perspectives: The Promise and Perils of Alternative Cancer Clinics ++++++

News & Perspectives: The Promise and Perils of Alternative Cancer Clinics https://www.medscape.com/viewarticle/promise-and-perils-alternative-cancer-clinics-2026a1000qp7?ecd=wnl_edit_tpal_etid8574839&uac=148436CN&impID=8574839 Scientists May Have a New Explanation for Excessive Sweating https://www.medscape.com/viewarticle/scientists-may-have-new-explanation-excessive-sweating-2026a1000qr1?ecd=wnl_edit_tpal_etid8574839&uac=148436CN&impID=8574839 Is Breast Really Best? https://www.medscape.com/viewarticle/breast-really-best-2026a1000q12?ecd=wnl_edit_tpal_etid8574839&uac=148436CN&impID=8574839 Friendly Physician Arrangements: How to Protect Yourself https://www.medscape.com/viewarticle/friendly-physician-arrangements-how-protect-yourself-2026a1000qd9?ecd=wnl_edit_tpal_etid8574839&uac=148436CN&impID=8574839 Pandora’s Message Portals https://www.medscape.com/viewarticle/pandoras-message-portals-2026a1000puh?ecd=wnl_edit_tpal_etid8574839&uac=148436CN&impID=8574839 Next Step for Australian UCCs: Ensuring Quality and Safety https://www.medscape.com/viewarticle/next-step-australian-uccs-ensuring-quality-and-safety-2026a1000p3c?ecd=wnl_edit_tpal_etid8574839&uac=148436CN&impID=8574839

Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer Authors: Peter Schmid, MD, PhD, FRCP; Kevin Kalinsky, MD, MS, FASCO; Frédérique Penault-Llorca, MD, PhD

https://www.medscape.org/viewarticle/clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h?page=1&src=mkmcmr_driv_stan_mscpedu_260806-OUS-HONC-clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h-cta&uac=148436CN

FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

New VA Video Connect features make telehealth appointments more accessible August 6, 2026 Treva Lutes Communications Specialist, Digital Health Office +++++

https://news.va.gov/148456/new-va-video-connect-appointments-accessible/?utm_medium=email&utm_source=govdelivery The Veterans Crisis Line isn’t only for a suicide crisis August 4, 2026 Dr. Steven Dobscha Acting Executive Director, Office of Suicide Prevention https://news.va.gov/148508/veterans-crisis-line-isnt-only-suicide-crisis/?utm_medium=email&utm_source=govdelivery Standing strong after the storm: Natural disasters fraud prevention August 5, 2026 Benefits Delivery Protection and Remediation, Veteran Benefits Administration https://news.va.gov/148481/standing-strong-after-the-storm-natural-disasters-fraud-prevention/?utm_medium=email&utm_source=govdelivery Live Whole Health #329: A simple sleep routine for snoozing smarter August 3, 2026 Andrea Young Health Systems Specialist with the Office of Patient Centered Care & Cultural Transformation https://news.va.gov/148517/live-whole-health-329-sleep-routine/?utm_medium=email&utm_source=govdelivery We've got more stories https://news.va.gov/news/health/?utm_medium=email&utm_source=govdelivery

Navigating Myelofibrosis-Associated Anemia Together: Empowering Collaboration and Communication Authors: Francesco Passamonti, MD

https://www.medscape.org/viewarticle/navigating-myelofibrosis-associated-anemia-together-2026a10007ks?page=1&src=mkmcmr_driv_stan_mscpedu_260805-OUS-HONC-navigating-myelofibrosis-associated-anemia-together-2026a10007ks-cta&uac=148436CN

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial Prof Rohit Loomba, MDa Send email to roloomba@health.ucsd.edu ∙ Prof Jacob George, MBBSb ∙ Prof Laurent Castera, MDc,d ∙ Prof Sven Francque, MDe ∙ Prof Eric Lawitz, MDf ∙ Ahsan Shoeb, MDg ∙ et al.

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial Prof Rohit Loomba, MDa Send email to roloomba@health.ucsd.edu ∙ Prof Jacob George, MBBSb ∙ Prof Laurent Castera, MDc,d ∙ Prof Sven Francque, MDe ∙ Prof Eric Lawitz, MDf ∙ Ahsan Shoeb, MDg ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00123-8/fulltext?dgcid=raven_jbs_etoc_feature_langas

Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial Prof John Burn, MDa,b Send email to john.burn@newcastle.ac.uk ∙ Dr Gillian M Borthwick, PhDa ∙ Faye Elliott, MScc ∙ Prof Finlay Macrae, MBBSd ∙ Kai Ren Ong, MDe ∙ Alison C Kraus, MDf ∙ et al.

Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial Prof John Burn, MDa,b Send email to john.burn@newcastle.ac.uk ∙ Dr Gillian M Borthwick, PhDa ∙ Faye Elliott, MScc ∙ Prof Finlay Macrae, MBBSd ∙ Kai Ren Ong, MDe ∙ Alison C Kraus, MDf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00114-7/fulltext?dgcid=raven_jbs_etoc_feature_langas